Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease
Identifieur interne : 000272 ( Main/Exploration ); précédent : 000271; suivant : 000273Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease
Auteurs : P. Stathis [Grèce] ; S. Konitsiotis [Grèce] ; G. Tagaris [Grèce] ; D. Peterson [Finlande]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-02-01.
English descriptors
Abstract
The efficacy and safety of levetiracetam (LEV), administered for management of levodopa‐induced dyskinesias (LID) in Parkinson's disease (PD), was examined using a multicenter, double‐blind, placebo‐controlled, parallel groups, crossover trial. Because of having a period effect, data after crossover point was excluded from analysis. Levodopa‐treated PD participants with LID (n = 38) received LEV 500 mg/day, were assessed, titrated to 1,000 mg/day and reassessed, before and after crossover. The placebo group followed the same routine. Primary efficacy was defined from percent change in “On with LID” time from patient diaries. Secondary efficacy assessment used “On without LID,” “Off” time, unified PD rating scale (UPDRS), clinical global impression (CGI), and Goetz dyskinesia scale after levodopa challenge. Safety measures were also performed. On with LID time decreased 37 minutes (95% confidence interval [CI] 0.59, 7.15; P = 0.02) at 500 mg/day, 7.85% 75 minutes (95% CI 3.3, 12.4; P = 0.002) at 1,000 mg/day. On without LID time increased by 46 minutes (95% CI −1.55, −0.03; P = 0.04) at 500 mg/day and 55 minutes (95% CI −10.39, −1.14; P = 0.018) at 1,000 mg/day. UPDRS 32 showed decreased dyskinesia duration mean change 0.35 (95% CI 0.09, 0.5; P = 0.009) at 1,000 mg/day. CGI showed LID decreased by 0.7 (95% CI 0.21, 1.18; P = 0.006) at 1,000 mg/day. Patient diaries and UPDRS show no increase in Off time. This exploratory trial provides evidence that LEV in 1,000 mg/day, slowly titrated, could be useful in improving LID as was assessed with patient diaries, UPDRS, and CGI scales, safely, with minimal side effects. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23355
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease</title><author><name sortKey="Stathis, P" sort="Stathis, P" uniqKey="Stathis P" first="P." last="Stathis">P. Stathis</name></author><author><name sortKey="Konitsiotis, S" sort="Konitsiotis, S" uniqKey="Konitsiotis S" first="S." last="Konitsiotis">S. Konitsiotis</name></author><author><name sortKey="Tagaris, G" sort="Tagaris, G" uniqKey="Tagaris G" first="G." last="Tagaris">G. Tagaris</name></author><author><name sortKey="Peterson, D" sort="Peterson, D" uniqKey="Peterson D" first="D." last="Peterson">D. Peterson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DF0BCEA51BDFE1D3B8FB4AC8EAC5E42318B388CD</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23355</idno><idno type="url">https://api.istex.fr/document/DF0BCEA51BDFE1D3B8FB4AC8EAC5E42318B388CD/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001893</idno><idno type="wicri:Area/Main/Curation">001646</idno><idno type="wicri:Area/Main/Exploration">000272</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease</title><author><name sortKey="Stathis, P" sort="Stathis, P" uniqKey="Stathis P" first="P." last="Stathis">P. Stathis</name><affiliation wicri:level="1"><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Neurology, 1st Hospital of Social Security Services, Athens</wicri:regionArea><wicri:noRegion>Athens</wicri:noRegion></affiliation></author><author><name sortKey="Konitsiotis, S" sort="Konitsiotis, S" uniqKey="Konitsiotis S" first="S." last="Konitsiotis">S. Konitsiotis</name><affiliation wicri:level="1"><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Neurology, University of Ioannina, Medical School, Ioannina</wicri:regionArea><wicri:noRegion>Ioannina</wicri:noRegion></affiliation></author><author><name sortKey="Tagaris, G" sort="Tagaris, G" uniqKey="Tagaris G" first="G." last="Tagaris">G. Tagaris</name><affiliation wicri:level="1"><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Neurology, “G. Gennimatas” General Hospital, Athens</wicri:regionArea><wicri:noRegion>Athens</wicri:noRegion></affiliation></author><author><name sortKey="Peterson, D" sort="Peterson, D" uniqKey="Peterson D" first="D." last="Peterson">D. Peterson</name><affiliation wicri:level="1"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Public Health, University of Kuopio, Kuopio</wicri:regionArea><wicri:noRegion>Kuopio</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-02-01">2011-02-01</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="264">264</biblScope><biblScope unit="page" to="270">270</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">DF0BCEA51BDFE1D3B8FB4AC8EAC5E42318B388CD</idno><idno type="DOI">10.1002/mds.23355</idno><idno type="ArticleID">MDS23355</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>levetiracetam</term><term>levodopa‐induced dyskinesias</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The efficacy and safety of levetiracetam (LEV), administered for management of levodopa‐induced dyskinesias (LID) in Parkinson's disease (PD), was examined using a multicenter, double‐blind, placebo‐controlled, parallel groups, crossover trial. Because of having a period effect, data after crossover point was excluded from analysis. Levodopa‐treated PD participants with LID (n = 38) received LEV 500 mg/day, were assessed, titrated to 1,000 mg/day and reassessed, before and after crossover. The placebo group followed the same routine. Primary efficacy was defined from percent change in “On with LID” time from patient diaries. Secondary efficacy assessment used “On without LID,” “Off” time, unified PD rating scale (UPDRS), clinical global impression (CGI), and Goetz dyskinesia scale after levodopa challenge. Safety measures were also performed. On with LID time decreased 37 minutes (95% confidence interval [CI] 0.59, 7.15; P = 0.02) at 500 mg/day, 7.85% 75 minutes (95% CI 3.3, 12.4; P = 0.002) at 1,000 mg/day. On without LID time increased by 46 minutes (95% CI −1.55, −0.03; P = 0.04) at 500 mg/day and 55 minutes (95% CI −10.39, −1.14; P = 0.018) at 1,000 mg/day. UPDRS 32 showed decreased dyskinesia duration mean change 0.35 (95% CI 0.09, 0.5; P = 0.009) at 1,000 mg/day. CGI showed LID decreased by 0.7 (95% CI 0.21, 1.18; P = 0.006) at 1,000 mg/day. Patient diaries and UPDRS show no increase in Off time. This exploratory trial provides evidence that LEV in 1,000 mg/day, slowly titrated, could be useful in improving LID as was assessed with patient diaries, UPDRS, and CGI scales, safely, with minimal side effects. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Finlande</li><li>Grèce</li></country></list><tree><country name="Grèce"><noRegion><name sortKey="Stathis, P" sort="Stathis, P" uniqKey="Stathis P" first="P." last="Stathis">P. Stathis</name></noRegion><name sortKey="Konitsiotis, S" sort="Konitsiotis, S" uniqKey="Konitsiotis S" first="S." last="Konitsiotis">S. Konitsiotis</name><name sortKey="Tagaris, G" sort="Tagaris, G" uniqKey="Tagaris G" first="G." last="Tagaris">G. Tagaris</name></country><country name="Finlande"><noRegion><name sortKey="Peterson, D" sort="Peterson, D" uniqKey="Peterson D" first="D." last="Peterson">D. Peterson</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000272 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000272 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DF0BCEA51BDFE1D3B8FB4AC8EAC5E42318B388CD
|texte= Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |